• Eli Lilly disclosed late-phase results from SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, already presented at European Congress on Obesity and published in The Lancet and Nature Medicine.
• Both studies showed patients largely sustained prior weight loss when switching off higher-dose injectable incretin therapy to once-daily oral Foundayo or to lower-dose Zepbound.
• Patients who stayed on maximum tolerated Zepbound maintained their earlier weight loss over an additional year, supporting longer-duration use without dose reduction.
• Readouts position Foundayo as an oral maintenance option for patients stepping down from injectable regimens, expanding Lilly’s portfolio across initiation and maintenance segments in chronic weight management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605121801PR_NEWS_USPR_____DE57002) on May 12, 2026, and is solely responsible for the information contained therein.